HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armstrong, D L Articles by Harding, J E Search for Related Content PubMed PubMed Citation Articles by Armstrong, D L Articles by Harding, J E

Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease

Department of Paediatrics, National Women's Hospital, Claude Road, Auckland, New Zealand

Correspondence to:
Correspondence to:
Professor Harding, Newborn Services, National Women's Hospital, Private Bag 92 189, Auckland, New Zealand;
j.harding{at}auckland.ac.nz

Objectives: To report 18 month outcome of a randomised trial of two courses of dexamethasone to prevent chronic lung disease of prematurity.

Study design: Babies of birth weight 1250 g or less ventilated at 7 days of age were randomised to a 42 day reducing course (long) or a 3 day pulsed (pulse) course of dexamethasone.

Growth, cardiovascular status, and respiratory and neurodevelopmental outcomes were assessed at 18 months.

Results: Seventy six babies were enrolled. Nine died and three were lost to follow up. Babies receiving the long course were weaned off oxygen more quickly than those receiving the pulse course (47% v 69% on oxygen at 28 days; p = 0.01), but there were no differences in 18 month outcomes. However, children averaged -1 SD for growth parameters, half had moderate or severe disability, and 35% and 19% respectively required oxygen at 36 weeks and discharge.

Conclusions: The dexamethasone course used did not influence long term outcome. However, entry criteria for this study selected a group of babies at high risk of poor long term outcome.

Keywords: preterm; steroids; respiratory disease; growth; development

This article has been cited by other articles:

				W. Onland, A. P. De Jaegere, M. Offringa, and A. H. van Kaam Effects of Higher Versus Lower Dexamethasone Doses on Pulmonary and Neurodevelopmental Sequelae in Preterm Infants at Risk for Chronic Lung Disease: A Meta-analysis Pediatrics, July 1, 2008; 122(1): 92 - 101. [Abstract] [Full Text] [PDF]

				L. K. Washburn, P. A. Nixon, and T. M. O'Shea Follow-up of a Randomized, Placebo-Controlled Trial of Postnatal Dexamethasone: Blood Pressure and Anthropometric Measurements at School Age Pediatrics, October 1, 2006; 118(4): 1592 - 1599. [Abstract] [Full Text] [PDF]

				T. F. Yeh, Y. J. Lin, H. C. Lin, C. C. Huang, W. S. Hsieh, C. H. Lin, and C. H. Tsai Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity N. Engl. J. Med., March 25, 2004; 350(13): 1304 - 1313. [Abstract] [Full Text] [PDF]